UBS Maintains Buy on Repligen, Lowers Price Target to $185
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Elizabeth Garcia maintains a Buy rating on Repligen (NASDAQ:RGEN) but lowers the price target from $205 to $185.

July 31, 2024 | 3:51 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
UBS analyst Elizabeth Garcia maintains a Buy rating on Repligen but lowers the price target from $205 to $185.
The Buy rating suggests continued confidence in Repligen's long-term prospects, but the lowered price target indicates some caution about short-term performance. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100